MedTrace Logo

Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair

NCT05610267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2024-06-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to collect additional safety data and demonstrate the performance of Integra Gentrix® Surgical Matrix for reinforcement of ventral hernia repairs.

Conditions

  • Ventral Hernia

Interventions

DEVICE

Retrospective chart review

The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).

Sponsors & Collaborators

  • Integra LifeSciences Corporation

    lead INDUSTRY

Principal Investigators

  • Adam Young, MD · Integra LifeSciences Corporation

Eligibility

Min Age
22 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-22
Primary Completion
2022-12-28
Completion
2022-12-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05610267 on ClinicalTrials.gov